Stockholders suing pharmaceutical distributor McKesson Corp. told a Delaware Chancery Court judge Thursday they had reached a $175 million settlement to resolve claims the company’s board failed in its oversight of opioid sales even after incurring millions in fines for previous compliance failures…

Read this piece in its entirety at Law360.